14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
THOR vs ICUI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, ICU Medical Inc (ICUI) is the stronger overall head-to-head candidate over THOR (THOR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). THOR carries a Unified Composite Score of 44.5/100 (HOLD) at $24.63 (N/M Forward P/E, N/A operating margin), whereas ICUI carries 49.5/100 (HOLD) at $172.52 (17.8x Forward P/E, 6.7% operating margin).
Technical & Structure Timing Caution: THOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.7); meanwhile ICUI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on THOR vs ICUI. Trailing 12-month operating profitability (THOR N/A vs ICUI 6.7%) and valuation multiples (THOR N/M vs ICUI 17.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $4.4B market capitalization and 6.7% operating margin.
OpEx & R&D Reinvestment32.2% of Rev ($703M)
90D Engineering Disclosures0 Published
Investor FAQ THOR vs ICUI Key Questions & Quantitative Answers
As of Nov 20, 2026, ICU Medical Inc (ICUI) is the stronger overall head-to-head candidate over THOR (THOR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). THOR carries a Unified Composite Score of 44.5/100 (HOLD) at $24.63 (N/M Forward P/E, N/A operating margin), whereas ICUI carries 49.5/100 (HOLD) at $172.52 (17.8x Forward P/E, 6.7% operating margin). Technical & Structure Timing Caution: THOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.7); meanwhile ICUI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ICUI leads the Growth & Scale pillar: THOR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ICUI at +4.4% YoY revenue growth and -46.9% YoY earnings growth on $2.18B TTM revenue (38.9% gross margin, 6.7% operating margin). On trailing 12-month operating scale, THOR generates N/A in USD-normalized revenue versus $2.18B for ICUI. In operating R&D and SG&A reinvestment, THOR deploys N/A (0 90-day corporate R&D disclosures) versus 32.2% of Rev ($703M) (0 disclosures) for ICUI.
ICUI screens cheaper on headline valuation multiples. THOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ICUI trades at 17.8x Forward P/E, 73.5x Trailing P/E, 0.09x PEG, and 2.0x EV/Revenue (15.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against THOR (N/A ROE) versus ICUI (2.8% ROE) capital efficiency.
In options market volatility and institutional positioning, THOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 17% Vol realized risk). By comparison, ICUI carries 39.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.86β · 38% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.